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Glenn M. LaMuraglia, MD, Boston, Mass
Objective: Photodynamic therapy (PDT) inhibits post-interventional stenosis in balloon-injured arteries, but causes
thrombosis when applied to vein grafts. This may result from added free radicals produced during the hypoxia-
reperfusion injury of vein graft implantation. The purposes of this study were to determine whether a free radical
scavenger could inhibit vein graft thrombosis, enabling PDT to inhibit intimal hyperplasia; and to investigate the role of
neutrophils, also a source of radicals, in this setting.
Methods: Jugular vein bypass grafts of the common carotid artery were performed in rats. PDT was administered in situ
to the vein graft and artery in the presence or absence of deferoxamine (DFX), an OH scavenger.
Results: PDT alone induced thrombosis in all untreated vein grafts. DFX administration or inhibition of neutrophil
adhesion to the graft prevented PDT-induced vein graft thrombosis. Moreover, DFX given together with PDT
significantly decreased vein graft intimal hyperplasia (0.010 mm2  0.005 mm2; P < .002) as compared with DFX alone
(0.113 mm2  0.009 mm2) or untreated control animals (0.112  0.007 mm2).
Conclusions: OH radicals and neutrophils both have key roles in PDT-induced vein graft thrombosis. By inhibiting free
radical production or neutrophil adhesion to the graft, adequate PDT can be administered for successful inhibition of
vein graft intimal hyperplasia. (J Vasc Surg 2004;39:843-9.)Autologous saphenous vein is the conduit most com-
monly used for cardiac and peripheral small-diameter by-
pass surgery. Despite good long-term patency, these recon-
structions can fail.1 During and after implantation into the
arterial circulation, vein grafts are exposed to a new envi-
ronment, which induces morphologic and functional
changes that can result in vascular stenosis and graft fail-
ure.2 Several approaches have been proposed to prevent the
development of intimal hyperplasia, the cause of stenosis in
vein grafts. These include gene therapy, nitric oxide do-
nors, drugs that modulate growth factors, and tissue factor
antagonists.1 While some show promise, their efficacy has
not been clinically demonstrated.
Another approach to this problem is use of photochem-
ical therapy. Photodynamic therapy (PDT) is a form of
photochemistry that makes use of light of a specific wave-
length to activate an otherwise biologically inert photosen-
sitizer to generate reactive species. PDT inhibits intimal
hyperplasia in experimentally injured arteries,3 and early
clinical trials indicate the feasibility and safety of PDT to
treat obstructive atherosclerotic lesions in patients.4-8
However, pilot studies in our laboratory performed to
investigate the use of PDT to prevent vein graft stenosis,
From the Division of Vascular Surgery of General Surgical Services, Massa-
chusetts General Hospital, Harvard Medical School.
Competition of interest: none.
Reprint requests: Glenn M. LaMuraglia, Harvard University, Massachusetts
General Hospital, Division of Vascular Surgery, WACC 464, 15 Parkman
St, Boston, MA 02114
0741-5214/$30.00
Copyright © 2004 by The Society for Vascular Surgery.
doi:10.1016/j.jvs.2003.11.028with the PDT dosimetry effective in arteries, led to acute
vein graft thrombosis. Lower dosimetry did not prevent
intimal hyerplasia (results not shown). There are several
reasons for this, some inherent to the unique characteristics
of the venous conduit. In addition, the vein graft under-
goes a relative hypoxia-reperfusion injury from its harvest-
ing in a relatively hypoxic environment to its implantation
into a relatively hyperoxic arterial circulation.1 During this
procedure free radical species are generated, which can
directly and indirectly cause cytotoxicity and tissue injury.1
This injury in turn causes cells to release cytokines and
chemokines, leading to neutrophil recruitment. Neutro-
phils adhere to the luminal surface of the vessel, where they
become activated and further potentiate the initial injury.
The neutrophil oxidative burst releases several free radicals
(superoxyde anion, hydrogen peroxide, hypochlorous
acid), which contribute to the vein graft injury.9-11
The primary hypothesis of this study was that intrinsic
free radicals generated by hypoxia-reperfusion during vein
implantation combine with exogenous PDT-generated re-
active species to create a prothrombotic environment in the
vein graft. On the basis of this premise, it is expected that
the pharmacologic reduction of intrinsic free radicals by
either an OH radical scavenger or an anti-neutrophil
antibody, which reduces the inflammatory infiltration to
the vein graft, will attenuate the initial injury. This should
thereby enable adequate dosimetry of PDT to be delivered
to the vein graft without inducing thrombosis. Once an
adequate dose of PDT can be delivered to the implanted
vein graft, intimal hyperplasia could be reduced.843
JOURNAL OF VASCULAR SURGERY
April 2004844 Nigri et alMATERIAL AND METHODS
Surgical procedures. Thirty-six Sprague-Dawley rats
weighing 350 to 400 g (Charles River Laboratories, Wil-
mington, Mass) underwent vein graft bypass of the left
common carotid artery with ipsilateral external jugular
vein. Anesthesia was induced with subcutaneous adminis-
tration of ketamine (75 mg/kg) and xylazine (7 mg/kg).
The left jugular vein was harvested through a midline
cervical incision, and was immersed in either saline solution
or deferoxamine solution (DFX; 250 mg/mL). A segment
of the ipsilateral common carotid artery was resected and
replaced with a 6-mm to 7-mm long vein graft anasto-
mosed end-to-end with 10-0 nylon suture (Ethicon, Som-
merville, NJ) without the use of heparin. The animal pro-
cedures were approved by the Institutional Animal Care
Committee, and complied with the Principles of Labora-
tory Animal Care and the Guide for the Care and Use of
Laboratory Animals (NIH Publication No. 80-23, revised
1985).
To test the driving hypothesis, control groups (Table I)
included untreated vein graft (C), and vein graft treated
with PDT (C-PDT), DFX (C-DFX), or URGE-8 anti-
neutrophil antibody (C-ANAb). Treatment groups in-
cluded vein graft treated with DFX and PDT (DFX-PDT),
and with antibody and PDT (ANAb-PDT). Another group
was added to test the efficacy of deferoxamine (FeDFX-
PDT).
Photochemical therapy. Immediately after vein graft
implantation all rats received the photosensitizer drug chlo-
roaluminum sulfonated phthalocyanine (5 mg/kg)
through the femoral vein. At 24 hours the neck incision was
reopened, and a right-angled mirror was placed underneath
the vein graft and the adjacent native artery. In the PDT
groups the surrounding tissues were optically isolated, and
the vein graft, including a 3-mm long cuff of artery adjacent
to both anastomoses, was externally irradiated with a
670-nm laser light emitted by a diode laser (B&W, Newark,
Del), with an irradiance of 220 mW/cm2. The C-PDT
group received a total fluence of 100 J/cm2, the standard
dose given for inhibiting arterial intimal hyperplasia. The
other PDT groups, given DFX, received a total fluence of
170 J/cm2. This fluence was chosen to show that there is a
safe dose range for achieving the benefits of PDT without











C, Control; PDT, photodynamic therapy; DFX, deferoxamine; ANAb,
anti-neutrophil antibody; FeDFX, iron-bonbed deferoxamine.induction of thrombosis. Nonirradiated control animals
underwent surgical reexposure of the carotid artery, but no
light irradiation. The patency of the grafts after the surgical
procedure was assessed with Doppler ultrasound scanning.
DFX and iron-loaded DFX. DFX was chosen as a free
radical scavenger because it can directly quench hydroxyl
radicals and indirectly block their production by inhibiting
the Fenton reaction.12,13 The vein grafts treated with DFX
were immersed in a DFX mesilate solution (103 mol/L;
Sigma, St Louis, Mo) for 20 minutes before implantation.
In addition, DFX (12 mg/kg intramuscularly) was admin-
istered systemically to the animals 1 hour before the bypass
procedure and 1 hour before PDT. To delineate the exact
role of DFX, iron-loaded deferoxamine (FeDFX; 98 mg of
ferric cloride in 250 mg/mL of DFX) was used in an
additional control group (FeDFX-PDT). FeDFX cannot
inhibit the Fenton reaction and therefore cannot block the
production of hydroxyl radicals.14
Anti-neutrophil antibodies. The role of neutrophils
in PDT-induced thrombosis was further investigated with
the monoclonal anti-neutrophil antibody URGE-8 (0.05
mg/kg in saline solution), which inhibits neutrophil adhe-
sion. URGE-8, which remains in the circulation for about
48 hours, was administered at the conclusion of the vein
graft bypass procedure. Injected animals were randomly
assigned to the control group (C-ANAb) or were adminis-
tered PDT (ANAb-PDT). Specimens were harvested 24
and 72 hours after surgery or PDT treatment. Lack of
neutrophil adhesion precluded long-term studies, because
of a high infection rate despite aseptic technique (data not
shown).
Vein graft harvesting and histologic analysis. Ani-
mals were killed, their aortas were flushed with saline solu-
tion, and subsequently perfusion-fixed at 80 mm Hg with
10% buffered formalin. Vein grafts, including 5 mm of
adjacent artery, were excised and placed in fresh 10% buff-
ered formalin for subsequent analysis. Longitudinal and
cross-sections were obtained along the vein graft body, at
the level of both anastomoses and at the proximal and distal
adjacent arterial segments. Paraffin-embedded sections (5
m) were stained with hematoxylin-eosin for histologic
evaluation.
Digital morphometric analysis. To quantify the
cross-sectional area of intimal hyperplasia and the diameter
of the vessel, digital morphometric analysis was performed
with an Olympus BH2 microscope (Olympus USA,
Melville, NY) connected to a Cohu color camera (Cohu,
Electronics Division, San Diego, Calif). The images were
processed with Scion Imaging Software (Scion Corp, Fred-
erick, Md). The intimal and medial areas were measured
and expressed in mm2. Vein graft diameters were calculated
from the internal elastic lamina and expressed in
millimeters.
Statistical analysis. All data within experimental
groups were expressed as mean SD. Differences between
groups were evaluated, where appropriate, with either one-
way analysis of variance or the Student t test. Statistical
significance was set at P  .05.
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The grafts in the control group (group C; n  8) were
all patent at harvesting. At 24 hours (n  2) histologic
analysis demonstrated lack of a continuous endothelial
layer, and numerous neutrophils adherent to the intimal
surface of the graft, with moderate inflammatory cell infil-
trate in the vessel wall. Occasional neutrophils were present
in the adventitial layer of the vein graft (Fig 1). The area
with the larger amount of intimal hyperplasia was the
proximal side of the distal anastomosis and therefore was
chosen as the site of measurement for morphometric anal-
ysis. Two weeks after surgery (n  6) there was typical
intimal hyperplasia consisting of six to eight layers of
smooth muscle cells. The mean intimal area was 0.112 
0.007 mm2, the medial area was 0.175  0.008 mm2, and
the diameter was 1.69  0.03 mm (Table II).
The vein grafts in the group treated with DFX only
(C-DFX; n  6) were all patent at harvesting. Histologic
findings, immediately and at 2 weeks, were similar to those
in group C. The specimens harvested after 24 hours also
showed neutrophils adhering to the vein graft intimal sur-
face. Findings at morphometric analysis at 2 weeks were
comparable with those in the control group (intimal area,
0.113 0.009 mm2, P .93; medial area, 0.175 0.008
mm2; diameter, 1.68 0.04 mm). In both control groups
(C and C-DFX) there was an increased presence of intimal
hyperplasia in the vein graft and in the adjacent artery close
to the level of the anastomosis (Fig 2).
In all animals that underwent vein graft interposition
bypass grafting and PDT (C-PDT; n  4; 100 J/cm2)
thrombus developed at the time of light irradiation. The
specimens were harvested at 24 hours, and showed com-
plete obliteration of the lumen, with dense neutrophil
infiltration of the thrombus (red thrombus), vessel wall,
and surrounding tissues.
The group treated with DFX and a higher PDT fluence
(DFX-PDT; n  7; 170 J/cm2) had no thrombosis at 24
hours. One of seven specimens demonstrated thrombus in
the vessel lumen, without complete thrombosis at 2 weeks
Fig 1. Histologic section demonstrates lack of a continuous en-
dothelial layer and numerous neutrophils (N) adhering to the
intimal surface of the graft in the control group 24 hours after
surgery. Inflammatory cell infiltrate in the vessel wall is moderate.
Occasional neutrophils are present in the adventitial layer of the
vein graft (A) (hematoxylin-eosin; original magnification 200).
Bar represents 100 m.(P  .001). The other six samples demonstrated a signifi-
cant reduction in intimal hyperplasia (0.010 0.005 mm2;
P  .002; Fig 3), as compared with control specimens
(groups C and C-DFX), with 91% intimal area reduction
(Fig 4, A). The medial area was 0.115  0.002 mm2, and
the diameter was 1.55  0.004 mm (Fig 4, B, C). These
samples also lacked endothelial covering of the intimal
surface, and rare inflammatory cells in the vessel wall or
intima were found. At morphometric analysis, only a few
samples had a small amount of intimal hyperplasia.
The FeDFX-PDT group (n  2; 170 J/cm2) demon-
strated acute complete thrombosis, similarly to the C-PDT
group. Animals treated with anti-neutrophil antibody alone
(C-ANAb) and with vein grafts harvested after 24 hours (n
 2) or at 72 hours (n  3) demonstrated only rare
neutrophils on the graft luminal surface and in the media
(150 neutrophils/mm2), compared with control specimens
(3660 neutrophils/mm2). Only rare inflammatory cells
were present on the adventitial layer. Specimens from ani-
mals that received anti-neutrophil antibody and PDT
(ANAb-PDT; n  4; 170 J/cm2) did not reveal the pres-
ence of any thrombus after 24 hours. However, over long-
term follow-up infection developed in all of these animals,
despite aseptic technique. Therefore morphometric data at
2 weeks for the ANAb-PDT group could not be obtained.
No animals demonstrated evidence of skin sensitivity to
the photosensitizer chloroaluminum sulfonated phthalocy-
anine. Postoperative recovery in the animals was not differ-
ent between groups, and no animals developed evidence of
neurologic deficit. No animals had wound infections, ex-
cept in the ANAb group.
DISCUSSION
The main objectives of this study were to address the
role of free radicals in PDT-induced thrombosis, the role of
neutrophils in this event, and the possibility of using a free
Fig 2. Area of vein graft in the control group demonstrates most
consistent intimal hyperplasia (IH) is just proximal to the distal
anastomosis; this area was used for morphometric analysis. Numer-
ous neutrophils are present in the adventitia (A) (hematoxylin-
eosin; original magnification 100). Bar represents 100 m.
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inhibit intimal hyperplasia. This study showed that free
radicals have a key role in PDT-induced thrombosis, as do
neutrophils, and that by using a free radical scavenger or
inhibiting neutrophil adhesion it is possible to deliver PDT,
which inhibits the development of intimal hyperplasia.
The use of photochemistry is useful in the treatment of
clinical entities such as esophageal dysplasia, lung neoplasia,
retinal neovascularization, and brain tumors.15,16 In the
cardiovascular field it succesfully inhibits intimal hyperpla-
sia and hinders the development of stenotic lesions in
experimentally injured arteries.3,17,18 This promising tech-
nique is being tested in clinical trials, with safety and
preliminary success.4,5,7,8,19 Far fewer studies have ad-
dressed the use of PDT to inhibit the development of
intimal hyperplasia in vein grafts.20-22 In the case of vein
grafts, PDT can decrease the development of intimal hy-
perplasia in the body of the vein graft but not in the
anastomosis when applied ex vivo.20 In this study animals
undergoing vein graft bypass surgery were treated in situ
with a fluence of 100 J/cm2, a dose effective for inhibiting
arterial intimal hyperplasia. However, at this fluence the
vein graft developed immediate and complete thrombosis
contrary to the arterial graft.23 Decreasing the dose of
either light or photosensitizer did not inhibit intimal hy-
perplasia (data not shown). Therefore, in an effort to de-
liver an adequate therapeutic dose of PDT, it became
important to understand the mechanism by which PDT
induces thrombosis in vein grafts, to prevent it from occur-
ring. The role of hydroxyl radicals and neutrophils in PDT-
induced thrombosis, the main obstacle to the application of
intimal hyperplasia-inhibiting PDT dosimetry, was there-
fore investigated.
Veins reside in an environment with low pressure and
low oxygen tension. After implantation, vein grafts are
exposed to the normal arterial pressure and oxygen settings
that are significantly higher than those in the venous sys-
tem. This extreme change of environmental conditions
leads to a relative hypoxia-reperfusion injury.2 The sudden
change in oxygen tension induces the production of free
radicals, such as superoxide anion, hydrogen peroxide, and
hydroxyl radicals. A major mechanism of hydroxyl radical
Fig 3. After 2 weeks, histologic section shows lack of intimal
hyperplasia in the deferoxamine–photodynamic therapy group
(DFX-PDT) group. In addition, partial reendothelialization (E) is
observed. Only rare neutrophils are present in the adventitia (A)
(hematoxylin-eosin; original magnification 200). Bar represents
100 m.production is the Fenton reaction, which is Fe depen-
dent.12 These free radicals result in tissue injury, through
membrane lipid peroxidation and protein denatur-
ation.12,24 In addition, the normal antioxidant defense
mechanism, involving catalase and glutathione peroxidase,
can be impaired when cells are injured.12 Moreover, the
production of free radicals upregulates the expression of
tissue factor and von Willebrand factor in endothelial cells
and mononuclear cells, setting up the extrinsic pathway of
coagulation.12 By developing this procoagulant environ-
ment, intrinsic free radicals generated by the hypoxia-
reperfusion injury during vein graft implantation could
synergize with PDT-generated reactive species and result in
observed vein graft thrombosis.
In fact, when a photosensitizer absorbs light of a spe-
cific wavelength, it is converted from a stable electronic
chemical structure (ground state) to an excited triplet state.
From the triplet state, either of two reactions follow. In a
type I reaction the photosensitizer can react directly with
other molecules, such as amino acids, forming free radicals.
In this case, hydrogen peroxide, hydroxyl radical, and su-
peroxide ion can be produced. In a type II reaction the
photosensitizer reacts directly with oxygen to produce
mostly singlet oxygen (1O ). The reactive species gener-
Fig 4. Morphometric analysis reveals significant reduction in in-
timal hyperplasia in the group treated with deferoxamine and
photodynamic therapy (DFX-PDT) (*P  .002 compared with
control groups C and C-DFX), with 91% intimal area reduction
(A) and 35% medial area reduction (B). C, Lumen diameter is not
significantly reduced.2
-neutr
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causing damage to cellular and organelle membranes.
It is hypothesized that oxygen-derived free radicals are
released in response to PDT. These cause damage to endo-
thelial cells and the vascular basement membrane, leading
to establishment of thrombogenic sites within the vessel
lumen. This triggers a cascade of events, including the
release of vasoactive molecules, increased expression of
tissue factor and von Willebrand factor in endothelial cells
and mononuclear cells, leukocyte adhesion, increases in
vascular permeability, and vessel constriction, setting up a
highly prothrombotic environment.12
To test this hypothesis that an excess of reactive moi-
eties results in vein graft thrombosis, animals were pre-
treated with DFX, an OH free radical scavenger. DFX is
used clinically to treat iron toxicity during red blood cell
transfusion or to treat iron overload. It is a small molecule
(mol wt 660) that can act in the intracellular or extracellular
space as an iron chelator, binding iron and thus preventing
the Fenton reaction, which produces hydroxyl radicals.
DFX can also act independently as a free radical quencher,
directly binding hydroxyl radicals.25 By administering DFX
in conjunction with PDT, thrombosis is inhibited, support-
ing the premise that intrinsic free radicals in the newly
implanted vein graft have a key role in PDT-induced
thrombosis. To further confirm that hydroxyl radicals have
a major role in the initial free radical-induced injury, which
contributes to the development of PDT-induced thrombo-
sis, DFX was loaded with iron (FeDFX) before administra-
tion in the vein graft or animal. In this form, FeDFX cannot
inhibit the Fenton reaction, although it can still be a free
radical quencher. As hypothesized, FeDFX did not inhibit
thrombosis after PDT application. This verified that inhi-
bition of the Fenton reaction and therefore the production
of free radicals, not performed by FeDFX, was necessary to
avoid thrombosis. DFX, by inhibiting the Fenton reaction
and directly quenching hydroxyl radicals, decreases the
total amount of oxygen-derived free radicals. This allows
delivery of an optimal dose of PDT to inhibit intimal
hyperplasia, without the induction of vein graft thrombosis.
DFX should be considered a “modulator” of PDT effects.
While appreciating the importance of hydroxyl radical
production in the development of PDT-induced thrombo-
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C, Control; PDT, photodynamic therapy; DFX, deferoxamine; ANAb, antisis, the question remained as to the role of neutrophils.
Neutrophils contribute to the initial hypoxia-reperfusion
injury response and are involved in hydroxyl radical produc-
tion. During the process of reperfusion multiple cellular
events lead to the release of cytokines and chemokines,
which recruit neutrophils. Neutrophils in turn potentiate
this initial injury by releasing superoxyde anion, hydrogen
peroxide, during the oxidative burst. These reactive moi-
eties can react in the Haber-Weiss reaction, to form highly
reactive hydroxyl radicals, which contribute to the vein
graft injury.9-11 The specific role of neutrophils and their
contribution to PDT-induced thrombosis was investigated
with the anti-neutrophil antibody URGE-8. URGE-8 re-
acts with a 45-kD cell surface antigen expressed primarily
on peripheral neutrophils and also on monocytes and lym-
phocytes.26,27 This antibody has been used to study the
function of neutrophils in acute pancreatitis, acute respira-
tory distress syndrome, acute myocardial infarction, and
acute hepatic failure, in which it can experimentally protect
the liver against ischemia-reperfusion injury.26,27 In the
present study, URGE-8 inhibited neutrophil adhesion and
infiltration in the vein graft. With no neutrophils present,
PDT application to the vein graft did not result in throm-
bosis. These findings support the hypothesis that the neu-
trophil contribution to direct or indirect free radical pro-
duction is crucial to the initiation of the cascade for PDT-
induced thrombosis.26,27
Once thrombosis was inhibited, it was possible to test
the assumption that PDT can inhibit the development of
intimal hyperplasia in the vein graft. Although DFX was
found to be a successful free radical scavenger in this model,
DFX administration alone (DFX-C) did not result in any
significant reduction in intimal hyperplasia at 2 weeks,
confirming the results of a previous study.28 Others report
some attenuation of intimal hyperplasia with continued
administration of DFX in animals after vein graft implanta-
tion.29,30 This suggests that reducing free radical produc-
tion only at the time of grafting is not sufficient to diminish
the injury response in the vein graft implanted. Therefore
the alternative solution of administering PDT together
with DFX not only avoids thrombosis but also enables
significant inhibition of intimal hyperplasia in the graft. A





0.175  0.008 1.69  0.03
Vein graft harvested at 24 h
Graft thrombosed at 24 h
0.175  0.008 1.68  0.04
t harvested at 24 h (n  2) or 72 h (n  3)
0.115  0.002 1.55  0.004
Graft partially thrombosed
Graft thrombosed at 24 h
No thrombus at 24 h
ophil antibody; FeDFX, iron-bonded deferoxamine.a
Graf
JOURNAL OF VASCULAR SURGERY
April 2004848 Nigri et al(170 J/cm2) to ensure that PDT dosimetry was well above
a pro-thrombotic dose. Systematic dosimetry testing was
not undertaken to identify the range of PDT application
that would still be effective for PDT of vein grafts so as to
avoid thrombosis but still enable inhibition of intimal hy-
perplasia, because it was not the primary objective of this
study.
The long-term effects of PDT combined with DFX on
vein grafts mirror many of the histologic findings noted in
PDT-treated arteries. At 24 hours there were no cells in the
intima, media, and adventitia of vein grafts with rare inflam-
matory cells present.3 This indicated that cells likely under-
went apoptosis, as described in PDT-treated arteries.31 The
compaction of the connective tissue in the vein graft wall
also indicates that matrix changes occurred, such as
crosslinking32 and modification of cytokines and chemo-
kines in the matrix.33-35 Histologic analysis at 2 weeks also
demonstrated the lack of cellular repopulation in the vein
graft wall, indicating that the barrier effect from PDT-
induced crosslinks in the matrix seen in arteries also occurs
in the vein graft.32
To conclude, the main objectives of this study were to
address the role of OH radicals in PDT-induced throm-
bosis, the contribution of neutrophils to this event, and the
possibility of using a radical quencher to administer PDT in
sufficient dosimetry to inhibit intimal hyperplasia. We
showed that Fenton reaction–generated OH radicals
have a key role in PDT thrombosis, as do neutrophils, and
that by using a free radical scavenger and PDT it is possible
to deliver PDT that inhibits thrombosis and the develop-
ment of intimal hyperplasia. This combination therapy may
pave the way to the clinical application of PDT, alone or as
adjuvant therapy, in preventing vein graft intimal hyperpla-
sia. Moreover, it may have a broader application in the
cardiovascular field in addition to vein grafting, such as in
treatment of atherosclerotic plaque, which has an inflam-
matory component that may contribute to an undesirable
prothrombotic mileau.
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